{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ignatius EH"],"funding":["HHS | National Institutes of Health","NIAID NIH HHS","Paratek Pharmaceuticals Inc"],"pagination":["e0038124"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11288010"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(7)"],"pubmed_abstract":["Treatment outcomes for <i>Mycobacteroides abscessus</i> (<i>Mab</i>, also known as <i>Mycobacterium abscessus</i>) disease are still unsatisfactory, mainly due to issues with drug toxicity, tolerability, and efficacy. Treating <i>Mab</i> disease is challenging due to its high baseline antibiotic resistance, initial requirement for intravenous therapy, and poor medication tolerance. Omadacycline, a new tetracycline, is active against <i>Mab</i>. Since any new antibiotic effective against <i>Mab</i> is expected to be used in combination with other antibiotics, we evaluated the efficacy of two triple-drug combinations comprising omadacycline, omadacycline + amikacin + imipenem, and omadacycline + clofazimine + linezolid against two contemporary <i>Mab</i> clinical isolates in a mouse model of"],"journal":["mSphere"],"pubmed_title":["Efficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of <i>M. abscessus</i> lung disease."],"pmcid":["PMC11288010"],"funding_grant_id":["K23 AI159145"],"pubmed_authors":["Belz DC","Lippincott CK","Lamichhane G","Serio AW","Rimal B","Panthi CM","Ignatius EH","Deck DH"],"additional_accession":[]},"is_claimable":false,"name":"Efficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of <i>M. abscessus</i> lung disease.","description":"Treatment outcomes for <i>Mycobacteroides abscessus</i> (<i>Mab</i>, also known as <i>Mycobacterium abscessus</i>) disease are still unsatisfactory, mainly due to issues with drug toxicity, tolerability, and efficacy. Treating <i>Mab</i> disease is challenging due to its high baseline antibiotic resistance, initial requirement for intravenous therapy, and poor medication tolerance. Omadacycline, a new tetracycline, is active against <i>Mab</i>. Since any new antibiotic effective against <i>Mab</i> is expected to be used in combination with other antibiotics, we evaluated the efficacy of two triple-drug combinations comprising omadacycline, omadacycline + amikacin + imipenem, and omadacycline + clofazimine + linezolid against two contemporary <i>Mab</i> clinical isolates in a mouse model of","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-06-02T09:19:24.096Z","creation":"2026-04-16T03:13:16.086Z"},"accession":"S-EPMC11288010","cross_references":{"pubmed":["38980071"],"doi":["10.1128/msphere.00381-24"]}}